EU Changes Mind on Nivo Plus Ipi for Kidney Cancer EU Changes Mind on Nivo Plus Ipi for Kidney Cancer
Positive opinions were given for the first-line use of the immunotherapy combination nivolumab and ipilimumab in kidney cancer and for an extension of indication for blinatumomab in certain leukemia patients.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
This review of 36 head-to-head trials found for all adverse events, the ranking was as follows for general safety (high to low): atezolizumab, nivolumab, pembrolizumab, ipilimumab and tremelimumab. Nivolumab had the best safety profile in lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 14, 2018 Category: Consumer Health News Source Type: news

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Radiation Could Make Mesothelioma Immunotherapy More Effective
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma. They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto. “There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - November 2, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news

FDA delays approval for BMS cancer therapy
Bristol-Myers said the marketing application submitted to the U.S. FDA for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 22, 2018 Category: Pharmaceuticals Source Type: news

Immunotherapy may become new first line treatment in some metastatic colorectal cancers
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. (1) The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (Source: World Pharma News)
Source: World Pharma News - October 22, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Major response to immunotherapy in early-stage mismatch repair deficient colon cancer
(European Society for Medical Oncology) Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Immunotherapy may become new first line treatment in some metastatic colorectal cancers
(European Society for Medical Oncology) Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Machine-learning driven findings uncover new cellular players in tumor microenvironment
(CytoReason) New findings presented today by CytoReason reveals possible new cellular players in the tumor microenvironment that could impact the treatment process for the most in-need patients -- those who have already failed to respond to ipilimumab (anti-CTLA4) immunotherapy. Once validated, the findings could point the way to improved strategies for the staging and ordering of key immunotherapies in refractory melanoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2018 Category: International Medicine & Public Health Source Type: news

Nivolumab vs Ipilimumab in Treatment of Advanced Melanoma Nivolumab vs Ipilimumab in Treatment of Advanced Melanoma
A new study compares nivolumab in combination with ipilimumab or nivolumab vs. ipilimumab monotherapy for extending overall or progression-free survival in adults with advanced melanoma.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma
(MedPage Today) -- Good survival outcomes, but high rates of toxicities, with ipilimumab-nivolumab combo (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 12, 2018 Category: Dermatology Source Type: news

CTLA4 targeted therapy plus PD-1 targeted therapy could benefit women with ovarian cancer
(NRG Oncology) An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer. These results were presented as a late-breaking abstract oral presentation at the 17th Biennial Meeting of the International Gynecological Cancer Society (IGCS) in Kyoto, Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 19, 2018 Category: Cancer & Oncology Source Type: news

Surgery for Mesothelioma No Longer Recommended in UK
Aggressive surgery for the treatment of malignant pleural mesothelioma (MPM) — unless part of a clinical trial — is no longer being recommended in the United Kingdom. The British Thoracic Society recently published its Mesothelioma Management Guidelines for 2018 and removed surgery from its recommendations. The belief was that potential harm was not worth the risk. The backtrack on surgery included the extrapleural pneumonectomy (EPP), the extended pleurectomy and decortication (P/D) and the partial pleurectomy (PP) — all of which are being done at cancer centers in the United States. “Surgery is a ...
Source: Asbestos and Mesothelioma News - September 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Drug Combo, Opdivo and Yervoy, Fights Melanoma That Has Spread to Brain
THURSDAY, Aug. 23, 2018 -- A combination of two drugs that work with the immune system can help beat back melanoma that has moved to the brain, an early clinical trial has found. The study included 94 patients with advanced melanoma that had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 23, 2018 Category: General Medicine Source Type: news

Dual Immunotherapy a Winner for Melanoma Brain Mets Dual Immunotherapy a Winner for Melanoma Brain Mets
A combination of two checkpoint inhibitors (nivolumab and ipilimumab) achieved'clinically meaningful'efficacy in patients with asymptomatic, untreated melanoma metastases to the brain.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab & #43; Ipilimumab Shows Efficacy for Untreated Brain Mets
WEDNESDAY, Aug. 22, 2018 -- For patients with melanoma and untreated brain metastases, nivolumab combined with ipilimumab shows clinically meaningful efficacy, according to a study published in the Aug. 23 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 22, 2018 Category: Pharmaceuticals Source Type: news

Bristol-Myers to get negative CHMP opinion on renal cancer drugs
Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

High-Dose Glucocorticoids for Hypophysitis Are Worse in Melanoma Patients
Melanoma patients who were treated with glucocorticoids for ipilimumab-induced hypophysitis had improved survival outcomes if they received low doses. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

BMS ’ Opdivo/Yervoy combo cleared for kidney cancer
Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.07/16/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 16, 2018 Category: Urology & Nephrology Source Type: news

Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.-- July 11, 2018 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval from the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 11, 2018 Category: Drugs & Pharmacology Source Type: news

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma
The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safe...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers find combination can enhance ipilimumab immunotherapy
(University of Texas M. D. Anderson Cancer Center) Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
Dave LevitanJun 6, 2018After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Dave LevitanJun 5, 2018Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
(Tonic Life Communications USA) Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy ® ). Current data show an overall response rate of 38 percent following treatment with the combination of tilsotolimod and ipilimumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2018 Category: International Medicine & Public Health Source Type: news

No Reliable Predictors for Ipilimumab-Induced Hypophysitis No Reliable Predictors for Ipilimumab-Induced Hypophysitis
Study results highlight the need for endocrine monitoring of all patients receiving checkpoint inhibitor immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Risk Factors for Ipilimumab-Induced Hypophysitis Remain Unclear
(MedPage Today) -- Researchers recommend close monitoring of these patients (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 18, 2018 Category: Dermatology Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 2, 2018 Category: Health Management Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 2, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 1, 2018 Category: American Health Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 1, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Preferred First-line Treatment for Metastatic Kidney Cancer Preferred First-line Treatment for Metastatic Kidney Cancer
Indirect comparisons suggest that of available agents, cabozantinib or nivolumab plus ipilimumab may be the most effective first-line treatment for metastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab/Ipilimumab Combo Approved for Advanced RCC
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA approves Opdivo, Yervoy combination for kidney cancer
The Food and Drug Administration has approved a combination of two immunotherapy drugs, ipilimumab and nivolumab, to treat metastatic kidney cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 17, 2018 Category: Consumer Health News Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

FDA approves new standard of care for kidney cancer
(UT Southwestern Medical Center) The US Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves IO Combo for Advanced Renal Cell Cancer FDA Approves IO Combo for Advanced Renal Cell Cancer
The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC
MONDAY, April 16, 2018 -- For metastatic non-small-cell lung cancer (NSCLC), the addition of pembrolizumab to standard chemotherapy is beneficial; and nivolumab plus ipilimumab is associated with better survival than chemotherapy for NSCLC with high... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2018 Category: Pharmaceuticals Source Type: news

Drug Combo Wins OK as First Line in Kidney Cancer
(MedPage Today) -- As shown in Checkmate 214 study, ipilimumab + nivolumab improve survival (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 16, 2018 Category: Urology & Nephrology Source Type: news

New Studies Show Immune Treatments Could Be Key in the Fight Against Lung Cancer
Researchers report some of the most encouraging results yet for treating lung cancer with the latest immune-based treatments, most of which have been approved to treat other types of tumors. In three papers presented at the American Association for Cancer Research annual meeting, and published simultaneously in the New England Journal of Medicine, lung cancer experts found innovative ways to weaken lung tumors to improve people’s chances of surviving the disease. “There is definitely a high unmet need,” says Patrick Forde, assistant professor of oncology and associate member of the Bloomberg-Kimmel Instit...
Source: TIME: Health - April 16, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer cancer immunotherapy Source Type: news

Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients
Another study combined Opdivo and Yervoy, two drugs made by Bristol-Myers Squibb, in lung cancer patients selected with a new type of diagnostic test. An third result hints that giving Opdivo earlier – before surgery to remove tumors – may lead to even more benefits for patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 16, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:MRK NYSE:BMY Source Type: news

Adjuvant Pembrolizumab for Melanoma -- Approval Imminent? Adjuvant Pembrolizumab for Melanoma -- Approval Imminent?
Pembrolizumab is poised to join the ranks of ipilimumab and nivolumab as adjuvant therapy for patients with stage III melanoma, after showing a 43% reduction in risk for recurrence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2018 Category: Drugs & Pharmacology Source Type: news

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer
WEDNESDAY, April 11, 2018 -- Gemcitabine and cisplatin (GC) plus ipilimumab is associated with a 69 percent objective response rate and 61 percent one-year overall survival for patients with metastatic urothelial cancer, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2018 Category: Pharmaceuticals Source Type: news